Barclays raised the firm’s price target on GoodRx to $9 from $8 and keeps an Overweight rating on the shares. The company’s Q4 report marked by a meaningful fiscal 2024 profitability guidance beat, a $450M share buyback and higher revenue growth on a like-for-like basis, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GDRX:
- GoodRx initiated with an Outperform at Leerink
- GoodRx Holdings Enhances Financial Stability and Restructures Leadership
- J&J lawsuit may spur adoption of GoodRx program, says Citi
- GoodRx price target raised to $6.50 from $6 at Goldman Sachs
- GoodRx to eliminate role currently held by Chief Operating Officer Raj Beri
